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Background/aim: The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic
asthma (SEA). However, reports on experience with mepolizumab in a real-life cohort are limited. Moreover, data about the effectiveness
of mepolizumab on small airways is scarce. This study evaluated the effectiveness of mepolizumab therapy on symptoms, asthma
exacerbations, blood eosinophils, steroid dependence, and small airways in a real-life cohort of patients with SEA.
Materials and methods: We retrospectively analyzed patients with SEA who were receiving fixed-dose mepolizumab. The effects of
mepolizumab on clinical, laboratory, functional parameters were evaluated at 12th, 24th, and 52nd weeks. Small airways were assessed
with the FEF 25-75.
Results: A total of 41 patients were enrolled in the study. Mepolizumab significantly reduced asthma exacerbation rates, reduced mOCS
dose, and improved asthma control test (ACT) scores at 12th, 24th, and 52nd weeks. However, we found no significant changes in FEV1
and FEF25-75 values at baseline, 12th, 24th, and 52nd weeks (78.9 ± 23.3%, 82.9 ± 23.4%, 81.9 ± 23.9%, and 78.9 ± 23.5% for FEV1; 45.1
± 23.1%, 48.8 ± 23.5%, 48.7 ± 23.1%, and 41.0 ± 20.1% for FEF25-75, respectively)
Conclusion: In this study, mepolizumab significantly improved all outcomes (symptom scores, asthma exacerbations, OCS sparing,
and blood eosinophils) except functional parameters. Still, despite the dose reduction in mOCS dosage, no significant deterioration was
observed in FEV1 and FEF25-75 values.
Key words: Mepolizumab, severe eosinophilic asthma, small airways, pulmonary function, asthma control test, oral corticosteroids

1. Introduction
Eosinophilic asthma generally refers to the clinical
inflammatory phenotype of asthma wherein a significant
number of sputum, airway, and/or blood eosinophils are
present [1]. Eosinophils are key effector cells in bronchial
inflammation and represent one of the main targets for
biological agents. Interleukin-5 (IL-5) is the pivotal cytokine
responsible for the maturation, activation, proliferation
and survival of eosinophils [2,3]. Therefore, IL-5 represents
a suitable specific target for biological treatments of severe
eosinophilic asthma (SEA). Mepolizumab is a humanized
IgG1/k monoclonal antibody which targets human IL-5
and thus prevents its interaction with the α chain of the
IL-5 receptor [4,5].
Previous effectiveness studies of mepolizumab
have clearly demonstrated that mepolizumab caused a

meaningful lowering effect on blood eosinophils, was
able to reduce asthma exacerbation rates, had a significant
glucocorticoid-sparing effect and improved symptom
control in asthma [6–9]. On the contrary, data regarding
post-marketing studies that have evaluated the effects of
mepolizumab in real-life settings are limited. Furthermore,
the data about the effectiveness of mepolizumab therapy
on small airways is quite limited in patients with SEA.
Therefore, we evaluated effectiveness of mepolizumab
on symptoms, asthma exacerbations, blood eosinophils,
steroid dependence, and small airways in the real-life
settings.
2. Materials and methods
This retrospective study included 41 severe asthmatics
who had been treated with mepolizumab between 2018
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and 2020. All patients were treated with high-dose inhaled
glucocorticoids (ICS) (extrafine hydrofluoroalkanebeclomethasone dipropionate), and a long-acting β2agonist, along with a second controller montelukast at
least 6 months and most of patients were receiving mOCS
therapy before the mepolizumab treatment. Indications to
be treated with mepolizumab were approved on the basis of
the Turkey Social Security Institution Health Application
Communique, according to which, mepolizumab can
be administered to patients with SEA having: a) blood
eosinophil count ≥300 cells/µL (≥150 cells/µL: If the
patient is under long-term regular OCS therapy); b)
controlled or uncontrolled asthma treated with regular
systemic steroids for at least 6 months and/or uncontrolled
asthma (relatively two attacks per year requiring systemic
corticosteroids for at least 3 days) despite use of a high
combination dosage of ICS (> 800 mcg/day budesonide or
equivalent) and inhaler long-acting β2 agonist for at least
one year [10].1
Throughout the study period, parameters including
mOCS (presented as methyl-prednisone equivalent in
milligrams), asthma control test (ACT) score, blood
eosinophil count, forced expiratory volume in 1 s (FEV1)
and FEF25-75 were measured at baseline, at week 12,
at week 24, and at week 52 after the first injection of
mepolizumab. In addition, the numbers of asthma
exacerbations were also recorded at baseline, week 24, and
week 52 (Figure 1).
All patients were under follow-up at our asthma
outpatient clinic provided written informed consent.
Ethical approval was obtained from the Erciyes University
Ethics Committee.
2.1 Definitions
2.1.1 Treatment response to mepolizumab
Mepolizumab was continued if there was a clinical response
at week 12. Responder: ACT variations were higher than
the accepted minimal clinically important differences
of three points in real life [10]. Eligibility of patients to
continue treatment was based on an increased in ACT
score of ≥3 from the baseline or clinically significant
reduced dose of mOCS without deterioration in ACT or
reduction of exacerbation rate by at least 50%.
2.1.2 Asthma exacerbations
An exacerbation was defined as worsening of asthma
symptoms, requiring OCS at least three days a week or an
increase in the mOCS dose.
2.1.3 Chronic rhinosinusitis with nasal polyposis
(CRSwNP)
CRSwNP is characterized by the occurrence for more
than 12 weeks of symptoms as nasal discharge, stuffiness,

facial pressure or pain, dysfunction or loss of the sense
of smell, and cough from post-nasal drip. The polypoid
inflammation filling the nasal airway in the paranasal
sinus computerized tomography (PNCT) [11,12].
2.2 Glucocorticoid reduction phase scheme
The dose of methylprednisone was reduced every four
weeks according to a predefined schedule (Table 1), if the
patient did not have an exacerbation with a decrease in
ACT score. In patients who were receiving a daily dose
of 8 mg or more of methylprednisone at baseline, the
dose of the drug was not reduced to 0 without consulting
to endocrinology due to concern regarding withdrawal
effects.
2.3 Pulmonary function assessments
Pulmonary function tests were performed at the Erciyes
University Medical Faculty Chest Diseases outpatient
clinic by trained and experienced respiratory function
test technicians of at least 5 years using a Vmax 20c
spirometre device while the patients were at a sitting
position. Following at least 3 acceptable maneuvers of
the pulmonary function test, the best test was recorded.
FEV1 (Forced expiratory volume in 1 s), FVC (forced vital
capacity), FEV1/FVC, FEF25-75 values were measured
and presented as the percentage of the expected value,
according to the patient’s age and height.
2.4 Statistical analysis
Data were entered into Statistical Package for Social
Sciences software v: 17.0 (SPSS Inc; Chicago, IL, USA),
and analyses were made using the same software program.
The distribution of continuous variables was tested with
the one-sample Kolmogorov– Smirnov test, and the
data are shown as mean ± standard deviation or median
and minimum–maximum intervals. For all parametric
variables, between group comparisons were made by using
repeated measures Anova. For all nonparametric variables,
between group comparisons were made by Friedman test,
and Dunnett’s multiple comparison test was made within
groups when the difference was statistically significant. A
p value of < 0.05 was considered to be significant in all
analyses.
3. Results
This study included 41 severe asthmatic subjects [nine
males (22%); mean age 48.8 ± 10.6; mean duration of
mOCS treatment 5.1 ± 4.0 months]. Baseline demographics
were presented in Table 2. Mean ACT scores were 16.6 ±
4.8 points at baseline. FEV1 and FEF25-75 values before
mepolizumab treatment found as 78.9 ± 23.2%, and 45.1
± 23.1%, respectively. Of the 41 patients, 35 (85.4%)
were receiving mOCS therapy before mepolizumab, with

Turkey Social Security Institution Health Application Communique. [Online]. Websıte: https://www.mevzuat.gov.tr/mevzuat?MevzuatNo=17229&
MevzuatTur=9&MevzuatTertip=5 [September, 2020].
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SEA who had been treated with
mepolizumab between 2018 and 2020
were retrospectively analyzed
(n:41)

at week 12 (n: 34)
mOCS,
ACT score
Blood eosinophil count
FEV1 and FEF25-75

Baseline (n: 41)
mOCS
ACT score
Blood eosinophil count
FEV1 and FEF25-75

at week 24 (n: 31)
mOCS
ACT score
Blood eosinophil count
FEV1 and FEF25-75
Asthma exacerbations

at week 52 (n: 21)
mOCS
ACT score
Blood eosinophil count
FEV1 and FEF25-75
Asthma exacerbations

Figure 1. Effects of mepolizumab on clinical, laboratory, and functional parameters were evaluated at 12th, 24th, 52nd weeks. Small
airways were assessed with the FEF25-75.
Table 1. Glucocorticoid reduction phase scheme.

Table 2. Characteristics of the patients.

Methylprednisolone dose (mg/day)

N = 41

20.0

16.0

12.0

10.0

8.0

6.0

4.0

Female sex n (%)

32 (78%)

16.0

12.0

10.0

8.0

6.0

4.0

2.0

Age, years, mean ± SD

48.8 ± 10.6

12.0

10.0

8.0

6.0

4.0

2.0

2.0*

Smoking n, (%)

10.0

8.0

6.0

4.0

2.0

2.0*

0.0

Never smoked

39 (95.1%)

8.0

6.0

4.0

2.0

2.0*

0.0

0.0

Ex-smoker

1 (2.4%)

6.0

4.0

2.0

2.0*

0.0

0.0

0.0

Active smoker

1 (2.4%)

4.0

2.0

2.0*

0.0

0.0

0.0

0.0

Asthma duration, years, mean ± SD

11.2 ± 5.8

2.0

2.0*

0.0

0.0

0.0

0.0

0.0

Mean follow-up duration, years ± SD

5.1 ± 1.9

2.0*

0.0

0.0

0.0

0.0

0.0

0.0

Methylprednisolone equivalent systemic
steroid dose before mepolizumab, mg, median
(min-max)

4 (0–16)

Nasal polyps, n (%)

22 (53.6%)

NERD, n (%)

16 (39%)

Atopy, n (%)

18 (43.9)

*Taken as 2.0 mg administered every other day.

a median dose of 4 mg. The median eosinophil count at
baseline was 450 (min-max, 10-2460) cells/µL.
3.1. Clinical efficacy of mepolizumab treatment on
severe eosinophilic asthma
Of the patients, 34/41 (83%) were continued the
mepolizumab treatment after 12 weeks. Seven patients were
not included in the 12 weeks assessment for mepolizumab
efficacy [5 were awaiting 12 weeks assessment, one stopped
due to adverse drug reaction (serum-sickness like disease),
one stopped due to difficulty in obtaining the drug before
12th week] (Figure 2). When comparing the change in
blood eosinophil counts, mOCS doses and ACT scores
between baseline and at week 12 under mepolizumab
treatment, a marked decrease in peripheral eosinophil
counts (3.7 (0.1–18)% vs. 1.3 (0.2–2.8)%; p < 0.001) and
an increase in ACT scores (17 (7–25) vs. 23 (14–25); p <
0.001) were observed. At week 12, all of the patients were
classified as treatment responders according to increased
ACT scores and decreased peripheral eosinophil counts

NERD: NSAID-exacerbated respiratory disease.

or decreased OCS dose without clinical deterioration.
mOCS dose was decreased in 27 of the 34 patients (79.4
%); oral corticosteroids were completely withdrawn in five
of the 34 patients. No marked changes in FEV1 values were
observed at this time point (78.9 ± 23.3% vs 82.5 ± 23.7%).
A total of 31/34 (91%) patients continued the
mepolizumab treatment after 24 weeks. Three patients
were not included in the 24 weeks’ assessment for
mepolizumab efficacy [two were nonresponders (6%),
one stopped due to adverse drug reaction in the “possible
category” (heart failure) before the 24th week] (Figure
2). Of the responders, 31/33 (94%) were still responders
at the 24th weeks’ assessment. After the 24th week under
mepolizumab treatment, the decrease in blood eosinophil
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41 patients

12th week assessment

• 5 not completed week 12
yet
• 1 adverse drug reaction
• 1 withdrawal by patient

34 patients
• 2 non-responders
• 1 adverse drug reaction

24th week assessment

31 patients
• 9 not completed week 52 yet
• 1 non-responder

52nd week assessment

21 patients

Figure 2. Number of patients evaluated at 12th, 24th, and 52nd weeks.

counts (baseline eosinophil count: 3.7 (0.1–18); 24th
week eosinophil count: 1.2 (0.2–4.7)%; p < 0.001) and
improvement in ACT scores (baseline ACT: 17 (7–25);
24th week ACT: 24 (15–25); p < 0.001) were continued.
mOCS dose was additionally reduced in 15 patients when
comparing to 12th week results. Daily oral corticosteroid
dose was withdrawn in 4 additional patients at week 24.
When compared to baseline, at week 24, a significant
decrease in the exacerbation rates within the last 24 weeks
was observed (1 (0–8) vs. 0 (0–0); p < 0.001).
A total of 21/31 (68%) patients continued
mepolizumab treatment after 52 weeks. Ten patients were
not included in the 52 weeks’ assessment for mepolizumab
efficacy (9 were awaiting 52 weeks assessment, one was
nonresponder before 52nd weeks) (Figure 2). Of the
responders, 21/22 (95%) were still responders at the 52
weeks’ assessment. After 52 week under mepolizumab
treatment, the decrease in blood eosinophil counts
(baseline eosinophil count: 6.2 ± 6.1%; 52nd week
eosinophil count: 1.2 ± 0.8%; p < 0.001) and improvement
in ACT scores (baseline ACT: 17 (7–25); 52nd week
ACT: 24 (17–25); p < 0.001) continued. mOCS dose was
additionally reduced in five patients when comparing to
24th week results. In total, the OCS dose of 18/21 (85.7%)
patients could be reduced at the end of 52 weeks. mOCS
treatment was withdrawn in four additional patients
at week 52. In total, 11/21 (52%) patients were able to
discontinue mOCS at the end of 52 weeks. At this time
point a significant decrease in the exacerbation rates
within the last 52 weeks was observed when compared
to baseline (1 (0–8) vs. 0 (0–3); p < 0.001). Comparison
of mOCS dose, number of asthma exacerbations, ACT
scores, and peripheral blood eosinophils at the beginning
of mepolizumab and at 12th, 24th, and 52th weeks after
treatment was shown table Table 3.
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3.2 Effect of mepolizumab treatment on pulmonary
functions in severe eosinophilic asthma
FEV1 values at 12th, 24th, and 52th weeks showed no
significant change when compared to baseline values
[2228 ± 906 mL (82.9 ± 23.4%), 2163 ± 856 mL (81.9 ±
23.9 %), 1976 ± 800 mL (78.9 ± 23.5 %) vs. 2117 ± 872
mL (78.9 ± 23.2%)]. Also, no marked changes in FEF25-75
values between the baseline and at 12th, 24th, and 52nd
weeks were observed [(1699 ± 1060 mL (48.8 ± 23.5%) ,
1675 ± 991 mL (48.7 ± 23.1%), 1378 ± 846 mL (41.0 ±
20.1%) vs. 1620 ± 1060 mL (45.1 ± 23.1%)]. Comparison
of FEV1, FEF25-75 at the beginning of mepolizumab and
at 12th, 24th and, 52nd weeks after treatment was shown
in Figure 3a and Figure 3b, respectively.
4. Discussion
Our study showed that mepolizumab therapy reduced
the rate of asthma exacerbations, decreased mOCS dose,
improved ACT scores, and decreased peripheral blood
eosinophil counts in patients with SEA. On the contrary,
we found no marked changes in FEV1 and FEF25-75 values
with 52-week mepolizumab add-on treatment.
We suggested that SC fixed-dose mepolizumab
administration significantly decreased blood eosinophil
levels, asthma exacerbations, mOCS doses and improved
ACT scores in patients with SEA in agreement with the
placebo-controlled studies and real life studies [6–9, 13–
15]. There were no significant change in FEV1 values after
12, 24, and 52 weeks of mepolizumab treatment, compared
to baseline in agreement with some studies [7,15–18]. Yet,
the important point here is that there was no deterioration
in pretreatment FEV1 values, and improved ACT scores
despite dose reduction or discontinuation of OCS.
The small airway impairment, as assessed with FEF2575 and might contribute to long-term persistent asthma
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Table 3. Comparison of the clinical, laboratory and functional parameters at the baseline, 12th, 24th, and 52nd week.
Pre-mepolizumab Mepolizumab 12th
n = 41
week n = 34

Mepolizumab
24th week n = 31

Mepolizumab
52nd week n = 21 p

*Methylprednisolone equivalent systemic
6 (0–16)
steroid dose, mg, median (min-max)

2 (0–8)

2 (0–4)

0 (0–4)

<0.001

*Number of asthma exacerbations in the
last 24 weeks, median (min-max)

1 (0–8)

0 (0–1)

0 (0–0)

0 (0–3)

<0.001

*ACT median (min-max)

17 (7–25)

23 (14–25)

24 (15–25)

24 (17–25)

<0.001

*Eos %, median (min-max)

3.7 (0.1–18)

1.3 (0.2–2.8)

1.2 (0.2–4.7)

1 (0.1–3.6)

<0.001

*Eos count, median (min-max)

450 (10–2020)

100 (10–240)

100 (20–470)

80 (10–280)

<0.001

FEV1 %, mean ± SD

78.9% ± 23.2

82.5 ± 23.7

81.9 ± 23.9

78.9 ± 23.5

0.459

FEV1 L/s, mean ± SD

2117 ± 872

2182.1 ± 878.7

2163.6 ± 856.9

1976.5 ± 800.3

0.329

FEF25-75%, mean ± SD

45.1 ± 23.1%

48.8 ± 23.5%

48.7 ± 23.1%

41.0 ± 20.1%

0.160

FEF25-75 mL, mean ± SD

1620 ± 1060

1699 ± 1060

1675 ± 991

1378 ± 846 mLL

0.085

ACT: asthma control test, eos: eosinophil.
*: The data difference between premepolizumab time and 12th, 24th, and 52nd weeks were all statistically significant (p < 0.001).

Figure 3a. Comparison of FEV1 at the beginning of mepolizumab
and at 12th, 24th, and 52nd weeks after treatment.

and the subsequent risk for poor asthma outcomes,
independently of large airway status [19]. Therefore, we
evaluated mepolizumab effectiveness on small airways
with mid expiratory flow rates. Despite no unanimous
consensus on the algorithm to assess small airway function
and structure, several noninvasive techniques can detect
small airway dysfunction. FEF25-75 is generally thought
to be more reflective of small airways obstruction than
is FEV1 [20,21]. Contrary to our expectation, we didn’t
find any significant improvement in FEF25%–75% with
mepolizumab effect on small airways. However, there was
no deterioration in pretreatment FEF25-75 values despite

Figure 3b. Comparison of FEF25-75 at the beginning of
mepolizumab and at 12th, 24th, and 52nd weeks after treatment.

dose reduction or discontinuation of OCS. To the best of
our knowledge, there are only two studies evaluating the
effect of mepolizumab on small airways in the literature. In
the first study conducted by Farah et al, mepolizumab could
significantly improve small airways in SEA measured with
multiple breath nitrogen washout [22]. The improvement
in small airway function was associated with asthma
control in the study [22]. Unlike this study, the absence
of changes in small airways in our study may result from
small airway assessment method differences. The nitrogen
washout method may be more sensitive than the FEF2575 measurement in detecting the change in small airways

1957

YILMAZ et al. / Turk J Med Sci
in patients receiving mepolizumab treatment [23,24].
On the other hand, our study cohort differed from this
study cohort. At baseline, our patient population were
younger and most of the patients was using mOCS, had
nasal polyposis and higher FEV1 values. In the second
study, Sposato et al. showed that FEF25-75 improved
after mepolizumab therapy in patients with SEA on the
contrary to our results [25]. Although both studies had
similar patient cohorts, different results were obtained. As
an explanation of this different results might be due to the
low number of patients in our study. Another explanation
is that the mOCS doses could be reduced rapidly within
3 months in majority of our cases because there was a
significant increase in the symptom scores of the patients
and the absence of asthma exacerbation. This decreasing
continued until the end of the 52nd week. Therefore,
while the dose of OCS can be reduced, we also reduce the
improving effect of OCS on small airways.
The limitation of the present study was its
retrospective design. Another limitation is that the
lack of validity of the FEF25-75 measurement to reflect
small airway functions and inflammation [26,27].
However, The FEF25–75 is the spirometric variable
most commonly cited as an indicator of small airway
obstruction in literature [28]. The small airways were
evaluated retrospectively with FEF25-75 values in our
study. If it was a prospective study and our primary

aim was to evaluate small airways, we could make a
comparison using one of the other methods to evaluate
small airways. In this way, we could more clearly evaluate
the effect of mepolizumab on small airways.
In conclusion, mepolizumab has been shown to
be effective in reducing exacerbations and daily doses
of mOCS in this real-life cohort of patients with SEA.
Although we found no improving effect of mepolizumab
therapy on small airways assessed with mid expiratory
flow rates there was no significant deterioration
compared to pretreatment FEF25-75 values, and there
were improved ACT scores despite dose reduction or
discontinuation of mOCS. Further studies comparing
the effectiveness of mepolizumab treatment on the small
airways with different techniques are needed.
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